Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
News Jul 10, 2012
Prokarium Ltd has completed a key technology acquisition from Emergent BioSolutions Inc., a global biopharmaceutical company based in Maryland, USA.
The technology includes Emergent’s live Salmonella-based typhoid vaccine Typhella™ and its genetic technology spi-VEC™.
Prokarium will combine Typhella™ and spi-VEC™ with its proprietary genetic and formulation technologies to form Vaxonella™, a versatile oral vaccine delivery platform.
Emergent has successfully conducted several phase 1 and 2 clinical trials, which have shown Typhella™ to be safe and immunogenic as a typhoid vaccine.
The combination with Prokarium’s plasmid stabilization technology ORT-VAC™, will enable the delivery of recombinant protein vaccines without needles or adjuvants.
Prokarium plans to offer this Vaxonella™ platform to the biotech community on a licensing basis.
Prokarium will focus on the development of a dual oral vaccine against typhoid and ETEC (enterotoxigenic E. coli - a major cause of diarrhoea) for travellers and developing country markets.
There are 22 million cases of typhoid every year resulting in 200,000 deaths, so an effective oral vaccine could have a significant impact.
Currently there is no dedicated vaccine against ETEC, considered responsible for 300,000 - 500,000 deaths per year, mostly of young children.
Dr Rocky Cranenburgh, Prokarium’s Chief Scientific Officer, said “I am delighted with the acquisition of this technology from Emergent; the combination of their Salmonella vector with Prokarium’s technologies allows us to develop an advanced oral delivery platform which gives Prokarium the potential to revolutionize vaccinations”.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018